This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
* Adult male patients (≥ 18 years old)
* with metastatic castration-resistant prostate cancer,
* who have initiated olaparib within at least, the last two months of study entry, at their physician's discretion or who have been enrolled in the funded early access program
* who have been informed and are not opposed to their data collection --- For Patients initiated with olaparib in fEA,
* Still alive and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician);
* who deceased and who did not object to data collection for research purpose(s) during his or her lifetime.
Exclusion criteria
* Patients opposed to the collection of their data
* Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
БГ